Study shows Novartis’ Cosentyx may modify course of psoriasis
admin 21st March 2017 Uncategorised 0Novartis has unveiled trial results which it says show that Cosentyx is the first and only IL-17A inhibitor to potentially modify the course of psoriasis.
More: Study shows Novartis’ Cosentyx may modify course of psoriasis
Source: News